Clinical Trial

Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 2, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast Cancer survivors (n=30) learn about heart health. The aims are to test the usability, feasibility, and acceptability o the intervention. Additionally, follow-up assessments will examine changes in women's cancer therapy related cardiac dysfunction knowledge and heart healthy behaviors (e.g., physical activity).
Protocol Amendment History 3 changes
critical Recruitment opened 2026-05-27
notable Primary completion pushed: 2026-06-30 -> 2026-07-30 2026-05-15
minor Completion pushed: 2026-06-30 -> 2027-02-28 2026-05-15
Trial Details
NCT Number NCT07426913
Lead Sponsor Virginia Commonwealth University
Conditions Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Virtual Reality, Trastuzumab
Enrollment 30 participants
Start Date 2026-05-20
Primary Completion 2026-07-30 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-02